Develops treatments for neurological and psychiatric disorders, focusing on innovative therapies.
Shuttle Pharmaceuticals Holdings, Inc., operates through its subsidiary, Shuttle Pharmaceuticals, Inc., with a primary emphasis on advancing innovative therapies aimed at enhancing the effectiveness of radiation therapy in cancer treatment. Established in 2012 and headquartered in Rockville, Maryland, the company specializes in the research, development, and commercialization of pharmaceutical products tailored to sensitize various types of cancers to radiation.
The company's current clinical pipeline features promising candidates such as Ropidoxuridine, an orally administered halogenated pyrimidine designed for patients grappling with brain tumors and soft tissue sarcomas. Additionally, Doranidazole, an injectable hypoxic cell radiation sensitizer, is being developed to address the treatment challenges posed by pancreatic, lung, and liver cancers. These efforts underscore Shuttle Pharmaceuticals Holdings, Inc.'s commitment to pioneering oncological therapies that aim to improve patient outcomes through targeted radiation sensitization strategies.
Driven by a mission to meet unmet medical needs in oncology, Shuttle Pharmaceuticals Holdings, Inc. continues to leverage its scientific expertise and strategic partnerships to advance novel treatment options. With a steadfast dedication to research and clinical advancement, the company remains focused on expanding its portfolio of radiation therapy sensitizers to benefit patients worldwide.